Table 1. Clinical and Utility Inputs.
| PUL | WVTT | Utility | Mean Time to Recovery (Days) | |||
| 0-3 Months | 4-12 Months | 0-3 Months | 4-12 Months | |||
| Mean IPSS (SD)* | 22.2 (5.5)9 | 11.5 (7.3)11 | 22.0 (4.8)10 | 10.3 (6.7)12 | 0.99 for mild LUTS17 0.90 for moderate LUTS17 0.79 for severe LUTS17 |
NA |
| Post-Procedure Catheterization | 51.4%9 | NA | 90.4%10 | NA | -0.0518 | 0.9 for PUL9 3.4 for WVTT10 |
| Adverse Events | ||||||
| Bladder Spasm | 3.6%9 | 0.7%9 | NA | NA | -0.0619 | 30.0‡‡ |
| Urinary Retention | 0.7%9 | 0.7%9 | 3.7%10 | 0.0%10 | -0.1819 | 30.7‡ |
| Urinary Tract Infection | 2.9%9 | 0.0%9 | 3.7%10 | 0.0%10 | -0.0719 | 13.3‡ |
| Pelvic Pain | 17.9%9 | 1.4%9 | 2.9%10 | 0.0%10 | -0.03** | 72.5‡ |
| Hematuria | 25.7%9 | 0.7%9 | 11.8%10 | 0.0%10 | -0.20† | 25.9‡ |
| Dysuria | 34.3%9 | 0.7%9 | 16.9%10 | 0.7%10 | -0.0319 | 38.2‡ |
| Urinary Urge Incontinence | 3.6%9 | 0.7%9 | 0.0%10 | 0.0%10 | -0.2019 | 30.0‡ |
| Frequency and Urgency | 7.1%9 | 2.1%9 | 5.9%10 | 0.0%10 | -0.03** | 53.2‡ |
| Encrusted Implants | 7.1%9 | NA | NA | -0.03†† | 30.0‡‡ | |
| Retreatment Type | ||||||
| PUL | 21.9%11 | NA | -0.03†† | 30.0‡‡ | ||
| WVTT | NA | 15.4%12 | -0.03†† | 30.0‡‡ | ||
| BPH Medical Therapy | 40.6%11 | 53.8%12 | -0.0319 | 30.0‡‡ | ||
| TURP | 37.5%11 | 23.1%12 | -0.0519 | 30.0‡‡ | ||
| Open Prostatectomy | 0.0%11 | 7.7%12 | -0.1620 | 30.0‡‡ | ||
Abbreviations: BPH, benign prostatic hyperplasia; IPSS, international prostate symptom score; LUTS, lower urinary tract symptoms; PUL, prostatic urethral lift; TURP, transurethral resection of the prostate; WVTT, water vapor thermal therapy.
*The mean and standard deviation of IPSS were captured at months 0 and 12.
**The disutility values of pelvic pain and frequency and urgency were not reported in Ackerman et al (2000).19 The disutility value of dysuria was applied due to the similarity of the symptoms.
†The disutility value of hematuria was assumed as -0.26 in a previously published economic analysis,21 which was greater than the disutility value of urinary urge incontinence, the highest disutility value in the model. Thus, the disutility value of urinary urge incontinence was assigned to hematuria.
††The disutility values of PUL, WVTT, and encrusted implants were not available. Thus, the disutility values of transurethral microwave thermotherapy reported in Ackerman et al (2000)19 was applied.
‡Unpublished data from the Rezum II trial.
‡‡Mean time to recovery assumptions with clinical validation by the expert were applied as the data were not available from the Rezum II trial.